.Attribute Medication, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) treatment of individuals along with HER2+ innovative breast cancer and active or even secure human brain metastases showed constant intracranial task and wide spread effectiveness of T-DXd.